High Quality 99% Montelukast Sodium Powder CAS 151767-02-1

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Frazer-Montelukast Sodium
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >99%
• Appearance: White Powder
• CAS No: 151767-02-1
• Shelf Life: 2 Years
• Test Method: HPLC
• MOQ: 1kg
• Storage: Store Cool Dry Place
• Resource: Natural
• Quality Requirement: Strictly Quality Control
• Mf: C35h35clnnao3s
• MW: 586.18
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 2000kg/Month

Product Description

High Quality 99% Montelukast Sodium Powder CAS 151767-02-1

 

Item	Specification
Description	White or off-white powder
Assay	≥99.0%
Identification
Chemistry	Must conforms to standard
Identification (HPLC)	The retention time of test sample major peak complies to reference standard
Infrared absorption	Must complies to reference standard
Sodium identification	The solution so obtained responds to the tests for sodium
pH	9.0~10.5
Impurity	Not more than 0.5% of any individual impurity is found, the sum of all impurities found is not more than 1.0%
S-isomer	NMT 1.0%
OVI	Must conforms to standard
Heavy metals	NMT 20ppm
Loss on drying	NMT 1.0%
microbe
Bacterium	NMT 1000 cfu/g
Mildew	NMT 100 cfu/g
Coliform	NMT 0 cfu/g

Function of Montelukast Sodium

Montelukast Sodium is a potent, selective, anti-inflammatory CysLT1 receptor antagonist (IC50 < 5nM) with no appreciable affecton the CysLT2 receptor. 
In rat colitis Montelukast Sodium has demonstrated the ability to increase PGE2 (Prostaglandin E2 - sc-201225) production and lower COX-2 expression.

Application of Montelukast Sodium

Montelukast Sodium is a potent, selective, anti-inflammatory CysLT1 receptor antagonist (IC50 < 5nM) with no appreciable affecton the CysLT2 receptor. In rat colitis Montelukast Sodium has demonstrated the ability to increase PGE2 (Prostaglandin E2 - sc-201225) production and lower COX-2 expression. Inhibition is competitive with respect to leukotrienes - particularly LTD4, a biologically active mediator that plays an important role in the control of several biochemical pathways involving pulmonary and immune system function. Because of its method of operation, it is not useful for the treatment of acute asthma attacks. Again because of its very specific mechanism of action, it does not interact with other asthma medications such as theophylline. Another leukotriene receptor antagonist is zafirlukast (Accolate), taken twice daily. Zileuton (Zyflo), an asthma drug taken four times per day, blocks leukotriene synthesis by inhibiting 5-lipoxygenase, an enzyme of the eicosanoid synthesis pathway.

Product Name	CAS No.	Product Name	CAS No.
Lufenuron	103055-07-8	Toltrazuril	69004-03-1
Nitenpyram	120738-89-8	Praziquantel/Biltricide	55268-74-1
Fenbendazole	43210-67-9	Tetramisole Hcl	5086-74-8
Levamisole	14769-73-4	Ponazuril	9004-4-2
Diclazuril	101831-37-2	Florfenicol	73231-34-2
Ivermectin	70288-86-7	Enrofloxacin Hcl	112732-17-9
Albendazole	54965-21-8	Mebendazole	31431-39-7